Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Valeo Pharma Inc. (VPHIF)
Kirkland, QC, CA
Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to sourcing, licensing, and selling a variety of medicinal products, with a primary emphasis on respiratory, specialized, and hospital-grade generic drugs. Its extensive product lineup features prominent asthma medications like Enerzair Breezhaler (a triple-combination LABA/LAMA/ICS) and Atectura Breezhaler (a dual-combination LABA/ICS). The company also offers Redesca, crucial for preventing and treating deep vein thrombosis and pulmonary embolism. For neurological conditions, Valeo markets Onstryv, an add-on treatment for Idiopathic Parkinson's Disease in patients on stable Levodopa, and Benztropine, an anticholinergic for PD. Pain management is addressed with M-Eslon, an extended-release morphine sulfate, while Yondelis targets soft tissue sarcoma. Beyond these, the portfolio includes Hesperco, an immune-supporting bioflavonoid antioxidant; Ametop, a skin anesthetic used before venous procedures; Ethacrynate Sodium, a loop diuretic for high blood pressure and swelling; and Amikacin, an injectable antibiotic. Founded in 2003, Valeo Pharma Inc. is headquartered in Kirkland, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.79% | -99.96% | -99.99% | -99.99% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+94.3% ★ Q3'24: -10.5% (vs Q3'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+0.0% Q3'24: -20.1% (vs Q3'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-43.8% Q3'24: +3.6% (vs Q3'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-26.0% Q3'24: -34.2% (vs Q3'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-80.9% Q3'24: +22,657.9% (vs Q3'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.5% Q3'24: +16.8% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-5.72× Q3'24: -4.76× (vs Q3'23)
| Metric |
Oct 2020 actual |
Oct 2021 actual |
Oct 2022 actual |
Oct 2023 actual |
Oct 2024 actual |
Oct 2025 actual |
Oct 2026 1 Rev. Ana. 1 EPS Ana. |
Oct 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
7.47M
est: 6.00M (+24.5%)
|
13.56M
est: 11.02M (+23.1%)
|
27.75M
est: 20.08M (+38.2%)
|
53.91M
est: 41.51M (+29.9%)
|
41.68M
est.
|
49.72M
est.
|
86.14M
86.14M – 86.14M
+73.2% YoY
|
89.46M
89.46M – 89.46M
+3.9% YoY
|
| EBITDA |
-3.74M
est: -3.14M (-18.9%)
|
-10.98M
est: -5.77M (-90.1%)
|
-16.10M
est: -10.52M (-53.0%)
|
-11.39M
est: -21.75M (+47.6%)
|
-21.84M
est.
|
-26.06M
est.
|
-45.14M
-45.14M – -45.14M
-73.2% YoY
|
-46.88M
-46.88M – -46.88M
-3.9% YoY
|
| EBIT |
-4.16M
est: -3.38M (-23.3%)
|
-11.38M
est: -6.20M (-83.6%)
|
-17.15M
est: -11.30M (-51.8%)
|
-14.02M
est: -23.36M (+40.0%)
|
-23.46M
est.
|
-27.98M
est.
|
-48.48M
-48.48M – -48.48M
-73.2% YoY
|
-50.35M
-50.35M – -50.35M
-3.9% YoY
|
| Net Income |
-4.76M
|
-14.23M
est: -13.75M (-3.5%)
|
-25.75M
est: -20.59M (-25.1%)
|
-27.81M
est: -19.34M (-43.8%)
|
-23.22M
est.
|
-12.05M
est.
|
13.57M
13.57M – 13.57M
+212.6% YoY
|
16.12M
16.12M – 16.12M
+18.7% YoY
|
| SGA |
5.45M
est: 4.96M (+9.9%)
|
16.19M
est: 9.10M (+77.9%)
|
24.90M
est: 16.58M (+50.2%)
|
29.15M
est: 34.29M (-15.0%)
|
34.43M
est.
|
41.07M
est.
|
71.15M
71.15M – 71.15M
+73.2% YoY
|
73.89M
73.89M – 73.89M
+3.9% YoY
|
| EPS |
-0.08
|
-0.20
est: -0.16 (-25.3%)
|
-0.32
est: -0.24 (-33.9%)
|
-0.32
est: -0.22 (-42.5%)
|
-0.27
est.
|
-0.14
est.
|
0.16
0.16 – 0.16
+212.6% YoY
|
0.19
0.19 – 0.19
+18.7% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kyle Steiger | Senior Vice President & Chief Commercial Officer | 226.0K | male |
| Frédéric Dumais | Director of Communications & Investor Relations | — | male |
| Guy-Paul Allard | Vice President of Legal Affairs & Corporate Secretary | — | male |
| Jean Francois Fournier | Head of Ophthalmology Business Unit | — | male |
| Pascal Tougas | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VPHIF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
